A recent HF compendium highlighted several translational successes, including the exciting prospects for SGLT2 inhibitors for heart failure with reduced ejection fraction (HFrEF) (McMurray et al., 2019) or heart failure with preserved ejection fraction (HFpEF) (Nassif et al., 2021), and tafamidis for transthyretin (TTR) cardiac amyloidosis (Maurer et al., 2018); yet strikingly, only one of the therapeutic approaches covered in several HF compendia was translated into a new therapy for patients with HF (Mann, 2021). This evidence concerns the gene TTR and heart failure.